The Effectiveness of Omeprazole and Esomeprazole in Infants (۱- ۱۱ Months of Age) with Gastroesophageal Reflux Disease: A Comparative Study
- سال انتشار: 1403
- محل انتشار: مجله بین المللی کودکان، دوره: 12، شماره: 1
- کد COI اختصاصی: JR_INJPM-12-1_006
- زبان مقاله: انگلیسی
- تعداد مشاهده: 113
نویسندگان
Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Department of Biostatistics, Kashan University of Medical Sciences, Isfahan, Iran
Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Student Research Committee, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Department of Pediatrics, School of Medicine, Infectious Diseases Research Center, Shahid Beheshti Hospital, Kashan University of Medical Sciences
Associated professor, Pediatric Department, Kashan University of Medical Sciences, Isfahan, Iran.
Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Student Research Committee, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
Department of Biostatistics and Epidemiology, Kashan University of Medical Sciences, Kashan, Iran.
چکیده
Background: Gastroesophageal Reflux Disease (GERD) is common in infants and its treatment remains extremely challenging in this age group. Therefore this study aimed to compare the efficacy and safety of omeprazole and esomeprazole in infants, aged ۱-۱۱ months old, presented with GERD. Methods: This double-blind randomized controlled trial was conducted on ۸۰ infants. All patients were randomly divided into omeprazole and esomeprazole treatment groups for four weeks. The signs, symptoms, and disease severity based on the Visual Analog Scale (VAS) of GERD were evaluated after treatment in both groups. The data were then analyzed using the SPSS Statistics software (version ۲۱). Results: The results of this study did not show significant differences between the mean disease severity based on VAS of both omeprazole- (۸۱.۱±۵۵.۷) and esomeprazole-receiving (۷۹.۱±۷۷.۶) groups (p=۰.۰۹۱). However, in each group, the mean disease severity after one month of treatment was significantly lower as compared to baseline (p< ۰.۰۱). The recovery rates were similar in both groups (۷۵% and ۷۰% for omeprazole and esomeprazole groups, respectively) (p=۰.۷۹۹). Conclusion: Omeprazole and esomeprazole did not have significant differences in signs, symptoms, and disease severity of GERD, however, we observed a significant reduction in disease severity in both groups indicating that these two drugs could be used interchangeably for the treatment of GERD disorder.کلیدواژه ها
Comparative Research,,, ,،Gastroesophageal Reflux Disease,,, ,،GERD,,, ,،Omeprazole,,, ,،Esomeprazole,,, ,،Infantsاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.